All Resources

Access to Medicine • November 10, 2022

Canadian Drug Access Pathway

Learn more | View

Economic Impact • October 07, 2022

Pre-Budget Consultations in Advance of the 2023 Budget

Learn more | View

April 28, 2022

Reflections on a Potential Pan-Canadian Drug Formulary: Medicines Industry Response to CADTH Consultation

Learn more | View

Access to Medicine • February 12, 2022

Optimizing Patient Access to Precision Therapies: Preparing for the Emerging Era of Advanced Testing

Learn more | View

Access to Medicine • February 05, 2022

Bluesky Project

Reimagining Canada’s Approval and Reimbursement System for Innovative Medicines February 2022…

Learn more | View

January 14, 2022

2022 Ontario Pre-Budget Consultation

Learn more | View

Drugs for Rare Diseases (DRD) • September 15, 2021

Addendum to IMC Submission on Drugs for Rare Diseases

Learn more | View

Drugs for Rare Diseases (DRD) • March 26, 2021

Towards a Value-based and Pan-Canadian Rare Disease Strategy

Learn more | View

January 30, 2021

Drug Reimbursement Timeline by Stages 2019-2020

Source: IMC analysis of IQVIA International Reimbursement Comparison data and IQVIA Public Reimbursement data. CADTH and provincial listing timelines are for drugs with a pCPA LOI in the respective year….

Learn more | View

Access to Medicine • August 20, 2020

IMC and BTC joint response to CADTH’s transparency consultation

IMC and and BIOTECanada write to Suzanne McGurn with joint input on the current CADTH process consultation….

Learn more | View

Patented Medicine Prices Review Board (PMPRB) • August 04, 2020

IMC Response to PMPRB 2020 Draft Guidelines

Learn more | View

Patented Medicine Prices Review Board (PMPRB) • February 14, 2020

IMC Response to PMPRB Draft Guidelines

Learn more | View